Cronos Group, Inc. (CRON)
3.38
0.00 (0.00%)
USD |
NASDAQ |
Aug 31, 15:40
Cronos Group Net Income (Quarterly) : 35.66M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 35.66M |
| March 31, 2026 | 15.71M |
| December 31, 2025 | -0.491M |
| September 30, 2025 | 28.32M |
| June 30, 2025 | -38.48M |
| March 31, 2025 | 7.723M |
| December 31, 2024 | 43.94M |
| September 30, 2024 | 7.324M |
| June 30, 2024 | -8.759M |
| March 31, 2024 | -2.484M |
| December 31, 2023 | -45.15M |
| September 30, 2023 | -1.59M |
| June 30, 2023 | -5.663M |
| March 31, 2023 | -18.04M |
| December 31, 2022 | -76.18M |
| September 30, 2022 | -33.10M |
| June 30, 2022 | -17.53M |
| March 31, 2022 | -32.65M |
| December 31, 2021 | -133.89M |
| September 30, 2021 | 77.58M |
| June 30, 2021 | -178.79M |
| March 31, 2021 | -161.60M |
| December 31, 2020 | -111.58M |
| September 30, 2020 | 68.94M |
| Date | Value |
|---|---|
| June 30, 2020 | -107.70M |
| March 31, 2020 | 75.68M |
| December 31, 2019 | 61.87M |
| September 30, 2019 | 604.16M |
| June 30, 2019 | 185.89M |
| March 31, 2019 | 313.99M |
| December 31, 2018 | -9.692M |
| September 30, 2018 | -5.561M |
| June 30, 2018 | 0.56M |
| March 31, 2018 | -0.8302M |
| December 31, 2017 | 1.623M |
| September 30, 2017 | 0.8746M |
| June 30, 2017 | 0.1301M |
| March 31, 2017 | -0.6381M |
| December 31, 2016 | 1.027M |
| September 30, 2016 | -0.1745M |
| June 30, 2016 | -1.429M |
| March 31, 2016 | -0.3568M |
| December 31, 2015 | 1.643M |
| September 30, 2015 | -0.3773M |
| June 30, 2015 | -0.4524M |
| March 31, 2015 | -2.791M |
| June 30, 2014 | -0.0094M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Lexaria Bioscience Corp. | -1.993M |
| Target Group, Inc. (Canada) | -0.2398M |
| Tilray Brands, Inc. | -37.93M |
| InMed Pharmaceuticals, Inc. | -2.792M |
| NervGen Pharma Corp. | -21.10M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 53.01M |
| Total Expenses (Quarterly) | 20.92M |
| EPS Diluted (Quarterly) | 0.0855 |
| Enterprise Value | 506.10M |
| Gross Profit Margin (Quarterly) | 52.96% |
| Profit Margin (Quarterly) | 67.28% |
| Earnings Yield | 5.45% |
| Normalized Earnings Yield | 5.858 |